Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$374 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.6 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
1.6
Industry P/E
--
EV/EBITDA
1.6
Div. Yield
0 %
Debt to Equity
0.1
Book Value
$2.5
EPS
$-2
Face value
--
Shares outstanding
108,569,143
CFO
$-777.85 Mln
EBITDA
$-996.40 Mln
Net Profit
$-1,088.84 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Rocket Pharmaceuticals (RCKT)
| 2.4 | -28.2 | 2.4 | -38.1 | -40.6 | -39.7 | -19.3 |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Rocket Pharmaceuticals (RCKT)
| -72.1 | -57.8 | 53.1 | -10.4 | -60.2 | 140.9 | 53.6 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Rocket Pharmaceuticals (RCKT)
|
3.6 | 374.0 | 0.0 | -223.1 | -- | -60.3 | -- | 1.6 |
| 61.3 | 8,072.9 | 1,091.0 | 202.3 | 31.6 | 31.3 | 36 | 14.2 | |
| 226.6 | 13,405.2 | 691.7 | -219.0 | -13.7 | 163.2 | -- | 14.6 | |
| 65.4 | 7,755.6 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 43.5 | 11,247.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 14.9 | 5.0 | |
| 92.0 | 11,306.9 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 7.3 | 6,847.2 | 113.3 | -351.4 | -211.0 | 71.1 | -- | 0.0 | |
| 529.2 | 11,592.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 16.8 | |
| 497.4 | 13,063.9 | 2,530.2 | 451.1 | 21.3 | 70.2 | 30.1 | 28.0 | |
| 309.9 | 7,699.1 | 0.0 | -303.3 | -- | -45.8 | -- | 8.8 |
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It... develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), which is in phase 1; and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is a form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart, which is in preclinical stage. It also develops ex vivo lentiviral (LV) programs, which include programs for Leukocyte Adhesion Deficiency-I (LAD-I), a genetic disorder that causes the immune system to malfunction (RP-L201); Fanconi Anemia (FA), a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells (RP-L102); and Pyruvate Kinase Deficiency (PKD), a red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia (RP-L301). It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red de Enfermedades Raras, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and Temple University. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey. Address: 9 Cedarbrook Drive, Cranbury, NJ, United States, 08512 Read more
CEO & Director
Dr. Gaurav D. Shah M.D.
CEO & Director
Dr. Gaurav D. Shah M.D.
Headquarters
Cranbury, NJ
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Rocket Pharmaceuticals Inc (RCKT) is $3.60 (NASDAQ) as of 02-Apr-2026 13:35 EDT. Rocket Pharmaceuticals Inc (RCKT) has given a return of -40.57% in the last 3 years.
Since, TTM earnings of Rocket Pharmaceuticals Inc (RCKT) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-1.75
|
1.41
|
|
2024
|
-4.74
|
2.65
|
|
2023
|
-10.25
|
5.11
|
|
2022
|
-6.43
|
2.91
|
|
2021
|
-8.32
|
3.10
|
The 52-week high and low of Rocket Pharmaceuticals Inc (RCKT) are Rs 8.26 and Rs 2.19 as of 03-Apr-2026.
Rocket Pharmaceuticals Inc (RCKT) has a market capitalisation of $ 374 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Rocket Pharmaceuticals Inc (RCKT), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-0.03
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.